News | Radiation Therapy | November 02, 2015

New CyberKnife, TomoTherapy Data Presented at ASTRO 2015

Results from several international studies show excellent treatment outcomes for a wide range of tumor types

Accuray, CyberKnife, TomoTherapy, clinical studies, ASTRO 2015

CyberKnife image courtesy of Accuray

November 2, 2015 — Accuray Inc. announced that studies on the clinical use of the CyberKnife and TomoTherapy systems continue to reinforce the devices' broad-based radiation treatment capabilities. More than 80 studies were presented during poster and oral sessions at the 57th Annual American Society for Radiation Oncology (ASTRO) meeting in October. Some of the studies presented show long-term efficacy and safety with median follow-up exceeding five years.

  • Data from China and Japan show faster treatment times and efficacy with TomoEDGE Dynamic Jaws

A study compared the plan quality and delivery efficiency of TomoHelical using TomoEDGE dynamic jaws to TomoHelical fixed-jaw delivery mode for nasopharyngeal carcinoma treatments. Results showed equivalent plan quality, with dynamic jaws mode providing a more efficient delivery and better sparing of the optic chiasm, pituitary and parotid glands when compared to fixed-jaw delivery mode. Clinicians affiliated with the Hong Kong Sanatorium & Hospital conducted the study.

An evaluation of stereotactic radiation therapy (SBRT) for brain metastases using TomoHelical in dynamic jaws mode found treatment time was reduced by 75 percent using this modality compared to treatment with fixed-jaw delivery mode, and at 12 months follow-up the local control rate was 100 percent. Research was conducted at five Japanese centers.

  • Long-term data (5 plus years) show excellent efficacy with both the CyberKnife and TomoTherapy Systems

Five-year physician-reported toxicity, survival, and relapse-free survival outcomes were reported for patients enrolled in a phase 2 prospective multicenter study evaluating SBRT for organ-confined prostate cancer using the CyberKnife System. The data indicate rates of serious adverse events have been minimal, with intermediate-risk patients experiencing high rates of overall and relapse-free survival. Physician-reported toxicities and relapse-free survival rates compared favorably to other radiation therapy modalities. Seven U.S. hospitals participated in the study, including Swedish Cancer Institute in Seattle, Washington, and Beth Israel Deaconess Medical Center in Boston, Massachusetts.

An additional study of the CyberKnife System for low and intermediate organ-confined prostate cancer showed a high rate of biochemical progression-free survival (95.8 percent and 90 percent for low- and intermediate-risk groups, respectively) with acceptable toxicity at a median follow-up of 84 months. Median prostate specific antigen (PSA) nadir was reached at four years and has remained unchanged for up to eight years, suggesting that the response is durable. Research was conducted at FROS Radiation Oncology and CyberKnife Center.

A study of patients with low, medium, or high-risk prostate cancer demonstrated that hypofractionated radiation therapy delivered using TomoHelical and simultaneous integrated boost (SIB) provides excellent results in terms of both efficacy and toxicity. Patients in all categories treated experienced a high rate of biochemical relapse-free survival and overall survival at five years follow-up, with low rates of acute and late toxicities. Research was conducted at San Raffaele Scientific Institute and Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy.

  • Clinical innovation in breast cancer and total marrow irradiation

A study examined the safety and efficacy of an accelerated dose/fractionation schedule delivered using the CyberKnife System after lumpectomy for selected patients with early-stage breast cancer. With a median follow-up of 27 months, all patients remained locally controlled with good to excellent cosmesis and no evidence of disease following treatment. Research was conducted at Winthrop University Hospital, Mineola, New York.

A phase 1-2 dose-escalation study evaluated the use of TomoHelical for total marrow irradiation (TMI) as the sole conditioning regimen for a second autologous stem cell transplant (ASCT) in recurrent leukemia patients. Full-body conformal radiation of the bone marrow enabled clinicians to successfully deliver a total dose of up to 1,800 cGy to the entire bony skeleton without dose-limiting toxicity. Median overall survival and progression-free survival were 3.8 years and 17.4 months, respectively. Research was conducted at the Ottawa Hospital Cancer Centre and the University of Ottawa, Ottawa, Ontario, Canada.

For more information: www.accuray.com

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Machine Learning Uncovers New Insights Into Human Brain Through fMRI
News | Neuro Imaging | January 11, 2019
An interdisciplinary research team led by scientists from the National University of Singapore (NUS) has successfully...
Mobile App Data Collection Shows Promise for Population Health Surveys
News | Population Health | January 10, 2019
Mobile app data collection can bring access to more potential clinical study participants, reduce clinical study...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Magnetic Resonance Imaging (MRI) | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Artificial Intelligence Pinpoints Nine Different Abnormalities in Head Scans

A brain scan (left) showing an intraparenchymal hemorrhage in left frontal region and a scan (right) of a subarachnoid hemorrhage in the left parietal region. Both conditions were accurately detected by the Qure.ai tool. Image courtesy of Nature Medicine.

News | Artificial Intelligence | January 07, 2019
The rise in the use of computed tomography (CT) scans in U.S. emergency rooms has been a well-documented trend1 in...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...